e-learning
resources
ERJ
2017
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis
Mirjam J.G. van Manen, Surinder S. Birring, Carlo Vancheri, Virginia Vindigni, Elisabetta Renzoni, Anne-Marie Russell, Monique Wapenaar, Vincent Cottin, Marlies S. Wijsenbeek
Source:
Eur Respir J, 50 (4) 1701157; 10.1183/13993003.01157-2017
Journal Issue:
October
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Mirjam J.G. van Manen, Surinder S. Birring, Carlo Vancheri, Virginia Vindigni, Elisabetta Renzoni, Anne-Marie Russell, Monique Wapenaar, Vincent Cottin, Marlies S. Wijsenbeek. Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis. Eur Respir J, 50 (4) 1701157; 10.1183/13993003.01157-2017
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Efficacy of Breathox® device inhalation on acute symptoms associated with COVID-19 (BREATH study)
A 12-year-old male child with fever, productive cough and sudden onset paralysis
A 41-year-old male with cough productive of yellow sputum and worsening breathlessness
Related content which might interest you:
Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function
Source: Eur Respir J 2016; 48: 843-851
Year: 2016
Effects of short-term pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis
Source: Eur Respir J 2006; 28: Suppl. 50, 628s
Year: 2006
Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Acute exacerbations of idiopathic pulmonary fibrosis and the role of corticosteroids
Source: Breathe, 16 (3) 200086; 10.1183/20734735.0086-2020
Year: 2020
Predictors of objective cough in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis
Year: 2019
Cough in idiopathic pulmonary fibrosis
Source: Eur Respir Rev 2016; 25: 278-286
Year: 2016
Exacerbation of idiopathic pulmonary fibrosis
Source: International Congress 2016 – Russia Session
Year: 2016
Idiopathic pulmonary fibrosis and pirfenidone
Source: Eur Respir J 2010; 35: 728-729
Year: 2010
Acute exacerbation of idiopathic pulmonary fibrosis
Source: Eur Respir J 2004; 23: 792
Year: 2004
Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients
Source: International Congress 2016 – IPF pathogenesis
Year: 2016
Pirfenidone in idiopathic pulmonary fibrosis
Source: Eur Respir J 2010; 35: 821-829
Year: 2010
Pirfenidone in idiopathic pulmonary fibrosis
Source: Eur Respir J 2010; 36: 695-696
Year: 2010
Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis
Source: Eur Respir J, 49 (5) 1601339; 10.1183/13993003.01339-2016
Year: 2017
Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Pulmonary hypertension in patients with idiopathic pulmonary fibrosis and combined pulmonary fibrosis and emphysema: hemodynamic severity
Source: International Congress 2018 – Pulmonary hypertension in lung diseases and the role of the right ventricle
Year: 2018
Patients with idiopathic pulmonary fibrosis and chronic obstructive lung disease leak inhaled nanoparticles to the blood.
Source: International Congress 2019 – Involvement of the environment and inflammation in pulmonary remodelling
Year: 2019
A comparison of pirfenidone versus nintedanib for the management of idiopathic pulmonary fibrosis
Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments
Year: 2018
Real-life comparison between pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis
Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia
Year: 2021
Asymmetry in acute exacerbation of idiopathic pulmonary fibrosis
Source: ERJ Open Res, 3 (2) 00036-2016; 10.1183/23120541.00036-2016
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept